Infuse Bone Graft
Medtronic, Inc. · Decision date Jul 28, 2026
What did the FDA approve?
FDA records P050053/S069 as a supplement to PMA P050053, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Jul 28, 2026.
FDA approval order statement
Approval to offer an alternatively configured Infuse Bone Graft kit in which the sterile water for injection (sWFI) vials, syringes, and needles have been removed from the kit, as well as minor labeling changes associated with this alternative kit configuration.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Dental
- Decision date
- Jul 28, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P050053/S069
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- NPZ
- Decision code
- APPR
- Decision date
- Jul 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Bone grafting material, dental, with biologic component.
- Applicant
- Medtronic, Inc.
- Product code
- NPZ
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P050053/S067 · Related supplement
INFUSE Bone Graft
P050053/S068 · Related supplement
INFUSE Bone Graft
P050053/S069 received
Application receipt date recorded by FDA.
P050053/S069 · FDA decision
Normal 180 Day Track
P050053/S066 · Related supplement
INFUSE BONE GRAFT
Timeline entries are records held by MedtechLedger for P050053. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P050053
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
INFUSE Bone GraftP050053/S067 | Medtronic, Inc. | PMA supplement | Feb 24, 2026 | FDA |
INFUSE Bone GraftP050053/S068 | Medtronic, Inc. | PMA supplement | Mar 19, 2026 | FDA |
INFUSE BONE GRAFTP050053/S066 | Medtronic, Inc. | PMA supplement | Aug 26, 2026 | FDA |
Explore the linked device profile
Other records with product code NPZ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Lynch Biologics, LLC | PMA supplement | Aug 3, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 1800 Pyramid Pl., Memphis, TN, 38132
Sources and methodology
- Original FDA record: P050053/S069
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


